Why the study?
Alternative adenoviral vectors are needed to expand receptor usage and circumvent vector immunity associated with prevalent human adenoviral vectors.
Nonhuman adenoviral vectors represent a promising platform for developing next-generation vaccines against infectious diseases by circumventing pre-existing immunity to human adenoviruses.
Answers are grounded in this paper and cite their sources.
May expand Ad vaccine options beyond human serotypes; leaves open clinical translation of nonhuman vectors.
Several human adenoviral (Ad) vectors have been developed for vaccine delivery owing to their numerous advantages, including the feasibility of different vector designs, the robustness of elicited immune responses, safety, and scalability. To expand the repertoire of Ad vectors for receptor usage and circumvention of Ad vector immunity, the use of less prevalent human Ad types or nonhuman Ads were explored for vector design. Notably, many nonhuman Ad vectors have shown great promise in preclinical and clinical studies as vectors for vaccine delivery. This review describes the key features of several nonhuman Ad vector platforms and their implications in developing effective vaccines against infectious diseases.
No takes yet. Share an insight, caveat, or question.
Alhashimi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: